August 2026– date –
-
Chinese iPSC-Derived Cardiomyocyte Therapy Significantly Improves Heart Function in 90% of Heart Failure Patients in Landmark Phase 2 Trial, Published in Nature Medicine
South China Morning Post China Overview A groundbreaking Phase 2 clinical trial conducted by Nanjing Drum Tower Hospital in China reported that 90% of heart failure patients who received iPSC-derived cardiomyocyte injections showed signi... -
DelveInsight Report: Over 12 Companies Enter iPSC-Derived NK Cell Therapy Pipeline, Led by Century Therapeutics and Fate Therapeutics
openPR.com (DelveInsight) India Overview This article provides an overview of a market research report published by DelveInsight, highlighting the rapid growth in the iPSC-derived NK cell therapy pipeline, with over 12 companies developi... -
Allogene Therapeutics’ TALEN-Edited Lymphoma Cell Therapy cema-cel Receives FDA RMAT and Fast Track Designations, Achieves 58.3% MRD Negativity in Phase 2 Trial
PRISM MarketView USA Overview Allogene Therapeutics' TALEN-edited allogeneic cell therapy, cema-cel, has received both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA, accelerating its regulatory pa... -
Bayer Continues Support for BlueRock Therapeutics’ CLARICO Eye Study of iPSC-Derived Photoreceptor Therapy OpCT-001 for Genetic Ocular Disease
TipRanks USA Overview Bayer AG announced continued support for BlueRock Therapeutics' CLARICO eye study, a Phase 1/2a trial evaluating the safety and early efficacy signals of OpCT-001, an iPSC-derived photoreceptor progenitor cell thera... -
BlueRock Therapeutics Advances iPSC-Derived Dopamine Neuron Therapy bemdaneprocel to Phase 3 for Parkinson’s, Demonstrating Significant Motor Improvement in Early Data
RegenMed Review USA Overview BlueRock Therapeutics' iPSC-derived dopamine neuron therapy, bemdaneprocel, is progressing to a Phase 3 trial (exPDite-2) for Parkinson's disease. Earlier 36-month Phase 1 data showed clinically meaningful im... -
FDA Lifts Clinical Hold on Intellia Therapeutics’ Phase 3 Trial for nex-z in Transthyretin Amyloidosis
Intellia Therapeutics (via LinkedIn) USA Overview Intellia Therapeutics announced the FDA has lifted the clinical hold on its Phase 3 MAGNITUDE-2 clinical trial for nexiguran ziclumeran (nex-z), a therapeutic candidate for transthyretin ... -
Intellia Therapeutics’ Gene-Editing Therapy lonvo-z Achieves 87% Reduction in HAE Attacks and 62% Attack-Free Rate in Phase 3 Trial
The Motley Fool USA Overview Intellia Therapeutics announced its in vivo gene-editing therapy, lonvoguran ziclumeran (lonvo-z), successfully met all primary and secondary endpoints in the Phase 3 HAELO trial for hereditary angioedema (HA... -
Vertex Pharmaceuticals’ CASGEVY Receives FDA Label Expansion for Over 5,500 US Children with Sickle Cell and Beta-Thalassemia, Driving Soaring Sales
ScanX USA Overview Vertex Pharmaceuticals' gene therapy, CASGEVY (exagamglogene autotemcel), received FDA label expansion for patients aged 2 and older with sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). This... -
Vertex Pharmaceuticals Initiates Phase 3 Trial for iPSC Islet Cell Therapy VX-880 for Type 1 Diabetes, Showing High Rates of Insulin Independence
Facebook (Breakthrough T1D) USA Overview Vertex Pharmaceuticals has launched a Phase 3 clinical trial for zimislecel (VX-880), its stem cell-derived islet cell therapy for severe type 1 diabetes. Prior trials demonstrated remarkable effi... -
Editas Medicine Stock Soars 14.4% on Q2 Revenue Beat, Investor Focus on Gene-Editing Pipeline Intensifies
MarketBeat USA Overview Editas Medicine reported a Q2 2026 revenue of $11.89 million, significantly surpassing analyst estimates of $2.85 million, alongside an adjusted EPS loss of $0.15, better than the projected $0.27 loss, leading to ...
